-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Chengdu Hengrui Pharmaceutical's Gliclazide sustained-release tablets and Jiangxi Pharmaceutical (a subsidiary of Renhe Pharmaceutical)'s Gliclazide sustained-release tablets were both approved as supplementary applications
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
The data show that Gliclazide extended-release tablets are mainly used for non-islet-dependent diabetes mellitus when dietary therapy alone is insufficient to control blood sugar, and its blood sugar lowering intensity is between tolbutamide and excellent blood sugar
.
.
The latest data from Minet.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
At present, 22 companies have the production approval for Gliclazide sustained-release tablets, of which 8 companies including Chengdu Hengrui Pharmaceutical, Jiangxi Pharmaceutical, Yichang Renfu Pharmaceutical, Shandong Lukang Pharmaceutical Group Saite have been approved with supplementary applications comment
.
.
In addition, 3 companies including China Resources Shuanghe Limin Pharmaceutical (Jinan) and Ningbo Keercom Minovar Pharmaceutical submitted their marketing applications under the category 4 imitations.
The supplementary application for sexuality evaluation is under review and approval
.
The supplementary application for sexuality evaluation is under review and approval
.
Source: State Food and Drug Administration official website, Minet database
A few days ago, the official website of the State Food and Drug Administration showed that Chengdu Hengrui Pharmaceutical's Gliclazide sustained-release tablets and Jiangxi Pharmaceutical (a subsidiary of Renhe Pharmaceutical)'s Gliclazide sustained-release tablets were both approved as supplementary applications
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
The data show that Gliclazide extended-release tablets are mainly used for non-islet-dependent diabetes mellitus when dietary therapy alone is insufficient to control blood sugar, and its blood sugar lowering intensity is between tolbutamide and excellent blood sugar
.
.
The latest data from Minet.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
At present, 22 companies have the production approval for Gliclazide sustained-release tablets, of which 8 companies including Chengdu Hengrui Pharmaceutical, Jiangxi Pharmaceutical, Yichang Renfu Pharmaceutical, Shandong Lukang Pharmaceutical Group Saite have been approved with supplementary applications comment
.
.
In addition, 3 companies including China Resources Shuanghe Limin Pharmaceutical (Jinan) and Ningbo Keercom Minovar Pharmaceutical submitted their marketing applications under the category 4 imitations.
The supplementary application for sexuality evaluation is under review and approval
.
The supplementary application for sexuality evaluation is under review and approval
.
Source: State Food and Drug Administration official website, Minet database
A few days ago, the official website of the State Food and Drug Administration showed that Chengdu Hengrui Pharmaceutical's Gliclazide sustained-release tablets and Jiangxi Pharmaceutical (a subsidiary of Renhe Pharmaceutical)'s Gliclazide sustained-release tablets were both approved as supplementary applications
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
.
The latest data from Minet shows that in 2021, the sales of Gliclazide sustained-release tablets in public medical institutions in China will be nearly 1.
2 billion yuan, of which Servier has the largest market share
.
The data show that Gliclazide extended-release tablets are mainly used for non-islet-dependent diabetes mellitus when dietary therapy alone is insufficient to control blood sugar, and its blood sugar lowering intensity is between tolbutamide and excellent blood sugar
.
.
The latest data from Minet.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
com shows that in 2021, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be nearly 1.
2 billion yuan.
Via has the largest market share, accounting for more than 50%
.
At present, 22 companies have the production approval for Gliclazide sustained-release tablets, of which 8 companies including Chengdu Hengrui Pharmaceutical, Jiangxi Pharmaceutical, Yichang Renfu Pharmaceutical, Shandong Lukang Pharmaceutical Group Saite have been approved with supplementary applications comment
.
.
In addition, 3 companies including China Resources Shuanghe Limin Pharmaceutical (Jinan) and Ningbo Keercom Minovar Pharmaceutical submitted their marketing applications under the category 4 imitations.
The supplementary application for sexuality evaluation is under review and approval
.
The supplementary application for sexuality evaluation is under review and approval
.
Source: State Food and Drug Administration official website, Minet database
